<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117594</url>
  </required_header>
  <id_info>
    <org_study_id>CCR 5035</org_study_id>
    <nct_id>NCT04117594</nct_id>
  </id_info>
  <brief_title>Whole Body Magnetic Resonance Imaging Study</brief_title>
  <acronym>WISE</acronym>
  <official_title>Whole Body Magnetic Resonance Imaging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In prostate cancer bone is the most common site for cancer spread, causing pain, fractures,
      nerve compression and death.

      New therapies are available for treating bone disease from cancer and this means that by
      maintaining patients on drugs that are effective and switching patients to other drugs when
      current treatment becomes ineffective, patients can be maintained 'better for longer'.
      However, to do this, it is necessary to accurately tell whether a given treatment is working
      or not.

      In this study, the investigators will perform whole body MRI scans, which include a special
      scan called diffusion-weighted MRI (DWI MRI) that can provide more information about the
      participants extent of disease. The investigators aim to show that this test is better than
      the standard tests of CT and bone scan currently used in the NHS to monitor bone disease. The
      information from this study will be used to test a special software so that the test may more
      widely benefit patients across the NHS in the future.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with prostate cancer the current methods to assess treatment response of bone
      disease such as computer tomography (CT) and bone scan (BS)are unreliable, insensitive to
      bone disease and have limited criteria to assess disease response confined to bones. Blood
      tests are inaccurate although some newer tests (e.g. circulating tumour cells tests) show
      promise but are still under investigation and nuclear medicine investigations such as PET/CT
      imaging have higher sensitivity, meaning they can detect more sites of disease who are indeed
      disease than CT or BS but they are more costly and less widely available compared with MRI
      within the NHS.

      For this study the Whole body MRI (WB-MRI) includes a measurement called diffusion-weighted
      imaging (DWI) which is relatively new and has a high sensitivity for bone metastases. This
      technique can be used to measure total bone disease volume (TDV) and the disease apparent
      diffusion coefficient (ADC) which reflects the tumour tissue cell density. Previous studies
      have shown good reproducibility of both these measurements and a significant increase in the
      mean tumour ADC is observed in patients who are responding to effective treatment.

      However WB-MRI application across the NHS is ad-hoc, CT and BS techniques are entrenched
      within clinical practice despite their known limitations. Another factor that limits wider
      adoption of WB-MRI is the lack of sophisticated analysis software to enable disease across
      the body to be quickly evaluated.

      This multi-centre imaging study will provide the opportunity to evaluate the performance of
      WB-MRI with a novel software diagnostics for evaluating the treatment response of advanced
      prostate cancer patients.

      This prototype can used to evaluate WB-MRI data from different scanners and address a current
      major unmet need for the treatment and follow-up of patients with bone disease from cancers,
      so that the test may more widely benefit patients across the NHS in the future.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of WB MRI at post treatment by quantification of bone disease</measure>
    <time_frame>End of Cycle 3 of treatment (each cycle being 28 days or 21 days depending on the type of standard therapy)</time_frame>
    <description>To establish the diagnostic performance of whole body MRI (WB MRI) using total bone disease volume (TDV) and disease apparent diffusion coefficient (ADC) at Cycle 3 (within 2 weeks before treatment on C4 Day1, each cycle being 28 days or 21 days depending on the type of standard therapy) using new software diagnostics for assessing treatment response to standard therapy (taxane chemotherapy or AR targeted agents)) in patients with bone predominant metastatic disease in prostate cancer using a construct reference standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare diagnostic performance of WB-MRI at Cycle 3 versus standard imaging CT and bone scan by quantification of bone disease</measure>
    <time_frame>End of Cycle 3 of treatment (each cycle being 28 days or 21 days depending on the type of standard therapy)</time_frame>
    <description>Compare the diagnostic performance of WB-MRI using TDV and ADC at Cycle 3 (within 2 weeks before treatment on C4 Day1, each cycle being 28 or 21 days depending on the type of standard therapy) with the diagnostic performance of standard imaging CT and BS (when available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression of responders and non-responders</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the time to progression of responders and non-responders to therapy as defined by WB MRI, versus CT and BS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-observer and inter-observer agreement of ADC and TDV</measure>
    <time_frame>1 year</time_frame>
    <description>Assess the intra-observer and inter-observer agreement of the apparent diffusion coefficient (ADC) and total diffusion volume (TDV) of bone disease assessed by WB-MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the cost-effectiveness of replacing CT and BS with WB-MRI derived measurements TDV and ADC</measure>
    <time_frame>1 year</time_frame>
    <description>Determine the cost-effectiveness of replacing CT and BS with WB-MRI derived TDV and ADC measurements for disease management in patients with prostate bone disease using QALYs.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Histogram parameters of ADC</measure>
    <time_frame>6 months</time_frame>
    <description>Explore histogram parameters of ADC in responders and non-responders to treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Histogram parameters of TDV</measure>
    <time_frame>6 months</time_frame>
    <description>Explore histogram parameters of TDV in responders and non-responders to treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Histogram parameters of fat fractions</measure>
    <time_frame>6 months</time_frame>
    <description>Explore histogram parameters of fat fractions in responders and non-responders to treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost and cost-effectiveness to the NHS of replacing the standard practice conventional tests</measure>
    <time_frame>1 year</time_frame>
    <description>Assess the cost and cost-effectiveness to the NHS of replacing the standard practice conventional tests CT and BS with WB-MRI-derived TDV and ADC measurements for disease management in patients with prostate bone disease using the advanced computer diagnostics software in development using QALYs and obtained from survival data and health-related quality of life.</description>
  </other_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Advanced Prostate Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>WB-MRI</intervention_name>
    <description>Whole body MRI with diffusion-weighted imaging (DWI)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced prostate cancer patients with bone predominant metastases and no RECIST-measurable
        disease (lymph nodes &lt;1.5cm in short axis in the pelvis are allowed) who have an indication
        for systemic treatment (taxane chemotherapy or AR targeted agents).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent

          2. Age â‰¥18 years

          3. Patients with APC with predominantly bone disease confirmed by bone scan (within 6
             weeks) or CT (within 6 weeks), of starting treatment (Cycle 1 Day 1). Patients with
             local recurrence and bone metastases with an associated soft tissue component, will be
             allowed into the trial. Pelvic lymphadenopathy &lt;1.5cm in short axis is not an
             exclusion.

          4. Systemic therapy indicated for disease progression, as clinically indicated.

        Exclusion Criteria:

          1. Patient is claustrophobic.

          2. Contraindications to MRI examination (e.g. cardiac pacemakers, cochlear implants).

          3. Measurable soft tissue or lymph node metastases or any metastatic disease outside the
             bone that is RECIST measurable will be an exclusion (unless it is pelvic nodal disease
             &lt;1.5cm in short axis). Bone metastases with associated soft tissue components will
             also not be an exclusion.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male patients with advanced prostate cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ana Ribeiro, MSc</last_name>
    <phone>0044 208661</phone>
    <phone_ext>3900</phone_ext>
    <email>ana.ribeiro@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy May</last_name>
    <phone>0044 208661</phone>
    <phone_ext>6624</phone_ext>
    <email>katherine.may@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Ribeiro</last_name>
      <phone>02086613900</phone>
      <email>ana.ribeiro@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Kathy May</last_name>
      <email>katherine.may@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Dow-Mu Koh, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nina Tunariu, Consultant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johann DeBono, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Blackledge, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alison Reid, Consultant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 26, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>WB-MRI</keyword>
  <keyword>Bone disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Fully anonymised trial data will be made available</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available within 1 year of study completion.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

